SSGJ-705 combined with chemotherapy

Phase 2Small molecule

SShenyang Sunshine Pharmaceutical Co., LTD.

SSGJ-705 combined with chemotherapy is one of 52 small molecule programs targeting Metastatic Solid Tumors. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Solid TumorsRecruiting

Combination TherapyRecruiting

Metastatic Solid TumorsPhase 2

Recruiting

Combination TherapyPhase 2

Recruiting

Competition

Competitive Landscape

48 competitors in Combination Therapy

#DrugCompanyPhaseTrials

Oncovin

Eli Lilly

Approved

1 2

Avastin

Roche

Phase 2

5 3

Liposomal Doxorubicin

Eli Lilly

Phase 3

1 4

Keytruda

Merck & Co.

Phase 2

3 5

Taxol

Teva

Phase 2

3 6

Beyfortus

BeiGene

Phase 2

3 7

Braftovi

Pfizer

Phase 2

1 8

Cabometyx

Bristol-Myers Squibb

Phase 2

1 9

Abraxane

Bristol-Myers Squibb

Phase 2

1 10

Taxotere

AAvyxa

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Combination Therapy

NCT07022002

Q4 2028

Phase 2Recruiting

Metastatic Solid Tumors

NCT07646626

Clinical

Trials by Indication[1]

Combination Therapy1 trial

SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors

Recruiting·SShenyang Sunshine Pharmaceutical Co., LTD.·Phase 2·NCT07022002·340 enrolled

Metastatic Solid Tumors1 trial

A Phase II Study of SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors

Recruiting·SShenyang Sunshine Pharmaceutical Co., LTD.·Phase 2·NCT07646626·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for SSGJ-705 combined with chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SSGJ-705 combined with chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SSGJ-705 combined with chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shenyang Sunshine Pharmaceutical Co., LTD. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShenyang Sunshine Pharmaceutical Co., LTD.

SSGJ-705 combined with chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2028

Trials by Indication[1]

Combination Therapy1 trial

Metastatic Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News